Drug intelligence / Profile preview

VCC-405567:02

Development stage: Preclinical
Lead developer: Vichem Chemie Research
Modality: Small Molecules

Overview

VCC-405567:02 is a preclinical-stage small molecule kinase inhibitor developed by Vichem Chemie Research. It acts as an ATP-competitive inhibitor targeting the PI3K-AKT-mTOR signaling pathway, with a reported mTOR IC50 of 748 nM. The PI3K-AKT-mTOR pathway is a critical regulator of cell growth, proliferation, and survival, and its dysregulation is frequently implicated in various cancers. VCC-405567:02 is being investigated in early discovery and hit-to-lead stages as a potential therapeutic agent for oncology and other diseases driven by aberrant kinase signaling.

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)RSK (RSK family)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on VCC-405567:02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCC-405567:02.